The targets of ICIs approved for cancer treatment are PD-1/programmed death ligand 1 (PD-L1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and lymphocyte activation gene-3 (LAG-3), and XPO1 inhibition has been shown to modulate the expression of these molecules. This evidence concerns the gene LAG3 and cancer.